282 related articles for article (PubMed ID: 34114495)
21. Fingolimod Improves the Outcome of Experimental Graves' Disease and Associated Orbitopathy by Modulating the Autoimmune Response to the Thyroid-Stimulating Hormone Receptor.
Plöhn S; Hose M; Schlüter A; Michel L; Diaz-Cano S; Hendgen-Cotta UB; Banga JP; Bechrakis NE; Hansen W; Eckstein A; Berchner-Pfannschmidt U
Thyroid; 2019 Sep; 29(9):1286-1301. PubMed ID: 31237525
[TBL] [Abstract][Full Text] [Related]
22. Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment.
Cho BY; Shong YK; Chung JK; Lee MC; Lee HK; Koh CS; Min HK
Thyroidology; 1989 Dec; 1(3):109-14. PubMed ID: 2484872
[TBL] [Abstract][Full Text] [Related]
23. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
[TBL] [Abstract][Full Text] [Related]
24. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
Gerding MN; van der Meer JW; Broenink M; Bakker O; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 2000 Mar; 52(3):267-71. PubMed ID: 10718823
[TBL] [Abstract][Full Text] [Related]
25. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
27. Autoimmunity and Graves' disease.
Bahn RS
Clin Pharmacol Ther; 2012 Apr; 91(4):577-9. PubMed ID: 22434030
[TBL] [Abstract][Full Text] [Related]
28. A case of pulmonary metastatic thyroid cancer complicated with Graves' disease.
Suzuki K; Nakagawa O; Aizawa Y
Endocr J; 2001 Apr; 48(2):175-9. PubMed ID: 11456264
[TBL] [Abstract][Full Text] [Related]
29. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
[TBL] [Abstract][Full Text] [Related]
30. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
[TBL] [Abstract][Full Text] [Related]
31. A TSHr-LH/CGr chimera that measures functional TSAb in Graves' disease.
Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Fiore E; Bucci I; Chamblin T; Vitti P; Monaco F; Napolitano G
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1106-15. PubMed ID: 22496495
[TBL] [Abstract][Full Text] [Related]
32. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
[TBL] [Abstract][Full Text] [Related]
33. TSHR as a therapeutic target in Graves' disease.
Smith TJ
Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991
[TBL] [Abstract][Full Text] [Related]
34. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
[TBL] [Abstract][Full Text] [Related]
35. Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves' Orbitopathy.
Khamisi S; Lundqvist M; Engström BE; Larsson A; Karlsson FA; Ljunggren Ö
Exp Clin Endocrinol Diabetes; 2023 Apr; 131(4):236-241. PubMed ID: 36706788
[TBL] [Abstract][Full Text] [Related]
36. Thyrotropin receptor antibodies and Graves' orbitopathy.
Diana T; Ponto KA; Kahaly GJ
J Endocrinol Invest; 2021 Apr; 44(4):703-712. PubMed ID: 32749654
[TBL] [Abstract][Full Text] [Related]
37. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
Aizawa Y; Yoshida K; Kaise N; Kaise K; Fukazawa H; Kiso Y; Mori K; Sayama N; Kikuchi K; Abe K
Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
[TBL] [Abstract][Full Text] [Related]
38. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
[TBL] [Abstract][Full Text] [Related]
39. Ability of monoclonal antibodies to the thyrotropin receptor to increase collagen synthesis in human fibroblasts: an assay which appears to measure exophthalmogenic immunoglobulins in Graves' sera.
Rotella CM; Zonefrati R; Toccafondi R; Valente WA; Kohn LD
J Clin Endocrinol Metab; 1986 Feb; 62(2):357-67. PubMed ID: 2416769
[TBL] [Abstract][Full Text] [Related]
40. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
